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CLINICAL PRACTICE ARTICLE

Acute Toxicity and Local Response using Three Fractions
of High Dose Rate (HDR) Brachytherapy for Curative
Treatment of Carcinoma Cervix
Nasir Ali, Bilal Mazhar Qureshi, Ahmed Nadeem Abbasi, Asim Haﬁz, Benazir Mir Khan and Abdul Qadir Jangda
Radiation Oncology Section, Department of Oncology, The Aga Khan University, Karachi, Pakistan

ABSTRACT
To determine the acute vaginal mucosal toxicity and clinical response of cervical cancer after deﬁnitive treatment with external
beam radiotherapy (EBRT) and three fractions each of 8 Fray (Gy) high dose rate intracavitary brachytherapy (HDR-BT).
Study Design: Descriptive study.
Place and Duration: Radiation Oncology Section, Department of Oncology, The Aga Khan University Hospital, Karachi,
Pakistan from January 2008 till December 2015.
Methodology: Protocol was formulated for carcinoma cervix to complete treatment in 7 weeks. Patients were treated with
chemotherapy and pelvic EBRT to a total dose of 45 Gy/25 fractions, followed by three intracavitary HDR brachytherapy fractions of 8 Gy each. Vaginal toxicity and local clinical response was assessed at the end of treatment, at 4 and 8 weeks.
Results: A total of 57 patients were treated with HDR brachytherapy and 49 patients were evaluated for assessment of
toxicity and response. According to FIGO staging system, two had stage IB2, one had IIA, thirty-six had IIB, seven had IIIB, one
had IVA disease and two had IVB with para aortic nodes. Concurrent gemcitabine and cisplatin were given to 26 (46%);
whereas, 28 (49%) received concurrent cisplatin alone. Grade III acute vaginal mucosal toxicity was seen in 52 and Grade IV
acute vaginal mucosal toxicity was observed in 08 patients. At completion of treatment, 40 patients had complete clinical
response, at 4 weeks follow-up, complete regression of disease was found in 3 more and at 8 weeks none had clinical residual
disease.
Conclusion: This regimen of HDR brachytherapy treatments is feasible, eﬃcacious, and well-tolerated for carcinoma cervix in a
setup with cost constraints. Long term toxicity and disease control remains to be reported with longer follow-up.
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INTRODUCTION
Cervical cancer is a disease of developing countries lacking
human papilloma virus screening; and ranks third most
common malignancy among females in Pakistan.1,2 The standard treatment for locally advanced cervical cancer is cisplatin
based concurrent chemoradiotherapy and brachytherapy.3
While brachytherapy is an integral part in the management of
cervical cancer, it is also established that entire treatment must
be completed in a speciﬁed time of 7-8 weeks.4
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In a series of 113 women diagnosed with stage IB to IIIB cervical
carcinoma, at a median follow-up of 26 months, time to completion of treatment more than 56 days was associated with a
higher rate of disease progression within the pelvis 26% versus
9%.5 Though American Brachytherapy Society (ABS) has recommended fractionation schedules of high dose rate
brachytherapy (HDR-BT) according to stage of disease, still
there is wide variation in prescribed fractionation schedule of
HDR-BT in literature.6 At the time of inception of HDR-BT
services at the study centre in late 2007, the authors empirically
formulated a three fractions schedule of brachytherapy with the
intention to complete entire treatment in 7 weeks duration,
used as three fractions HDR brachytherapy of 8 Gy each in these
patients. It was important to evaluate the grade of vaginal
mucosal toxicity and response of local disease at completion of
treatment and on early follow up by clinical examination for this
treatment.
The aim of this study was to report acute vaginal mucosal
toxicity and clinical response of cervical cancer after deﬁnitive
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treatment with external beam radiotherapy (EBRT) and three
fractions each of 8 Gray (Gy) high dose rate intracavitary
brachytherapy (HDR-BT).

phamide chemotherapy then subjected to left modiﬁed radical
mastectomy followed by left chest wall and regional nodal radiation therapy.

METHODOLOGY

HDR brachytherapy was delivered at 8 Gy per fraction with
weekly interval, ﬁrst fraction of brachytherapy was delivered
during last week of EBRT and, EBRT fraction was not delivered
on the day of HDR-BT as shown in Table I of road map to cervical
cancer treatment. Irredium-192 HDR treatment was used with
GammaMed machine. The selection of applicator was done by
the radiation oncologist on vaginal examination before
brachytherapy procedure between either Fletcher Suit Delclos
Tandem and Ovoid applicators or Tandem and Ring applicators.
HDR-BT dose was prescribed at right and left point A. Insertion of
applicators were done under general anesthesia. Careful
vaginal packing was done to displace the bladder and rectum
away from the applicators (Figures 1 and 2). HDR treatment
planning was performed on Abacus treatment planning in ﬁrst
half of the total duration and on Eclipse planning system in
second half of study period.

After the inception of HDR-BT services at the Aga Khan University, a road map was developed for the treatment of cervical
cancer patients with the aim to complete the treatment in seven
weeks. It was mandatory for all patients to undergo pelvic examination under general anesthesia for staging and biopsy of
cervical mass and cystoscopy and procto-sigmoidoscopy whenever required; systemic staging work up comprised of contrast
enhanced CT scan of chest abdomen and pelvis. Therefore, all
the patients with locally advance cervical cancer were managed,
after pretreatment evaluation with the treatment scheme
mentioned below, from January 2008 till December 2015.

After staging and pre-treatment workup, patients started treatment with external beam radiation therapy (EBRT) and concurrent weekly chemotherapy, preferably on ﬁrst day. Patients
were evaluated and considered for smit sleeve insertion in
fourth week of treatment under general anesthesia by gynaeoncologist. First fraction of brachytherapy was delivered during
fourth or ﬁfth week of treatment before completion of external
beam radiation therapy. Patients did not receive EBRT on the
day of brachytherapy.
All patients were treated with concurrent chemotherapy and
EBRT and HDR-BT. CT based 3-D conformal EBRT planning was
preferred. The dose of EBRT consisted of 4500 cGy over 25 fractions on 18MV linear accelerator over ﬁve weeks. Superior limit
of the anterior and posterior ﬁeld was kept at L4-5 junction, inferior border was kept 2- 3 cm below the palpable tumor in vagina
or at base of obturator foramen, whatever was inferior. Laterally, the ﬁeld extended 2 cm to the bony margin of pelvis. Lateral
ﬁeld borders were placed at the 2nd and 3rd sacral space at posterior margin and anterior border was placed at the anterior
cortex of pubic symphesis. Cranio-caudal length of lateral ﬁeld
was equal to the length of anterio-posterior ﬁelds. However, in
patients with para aortic lymphadenopathy superior border of
the ﬁelds was placed at top of twelfth thoracic vertebra. Multi
leaf collimators were used to block the normal tissue as much as
possible without compromising the dose to the planning target
volume (PTV).
Concurrent chemotherapy during EBRT was part of treatment
plan. Patients receiving single agent cisplatin got dose of 40
mg/m2 every week. Patients receiving doublet chemotherapy
had cisplatin 40 mg/m2 and gemcitabine 125 mg/m2 on weekly
basis. This was followed by adjuvant two cycles of same
chemotherapy, i.e. cisplatin 50 mg/m2 on day 01, gemcitabine
1000 mg/m2 on day 01 and 08, cycle to be repeated at 3 weeks
interval. One patient had second primary of locally advanced
left breast cancer as well, so she received carboplatin at the
dose of area under the curve (AUC) 5, and paclitaxel 80 mg/m2
weekly during pelvic EBRT, and after completion of radiation
therapy she received four cycles of Adriamycin and cyclophos-

Acute vaginal mucosa toxicity was recorded at conclusion of
HDR brachytherapy, and four and eight weeks after completion
of treatment according to the Common Terminology Criteria for
Adverse Events (CTCAE) Version 4.0.7 Toxicity assessment
results were recorded in patient’s conﬁdential records.
Tumor bi-dimensional measurements were recorded at start of
treatment and response was done by bi-dimensional measurement of cervical mass by the same physicians after completion
of treatment. During concurrent chemoradiotherapy complete
blood count and serum creatinine were checked in all the
patients at weekly interval.
After completion of treatment, patients were followed every
two months in ﬁrst year, three months in second and 6 monthly
in the subsequent years. Follow up was done by physical examination, cervical cytology, and when required by pelvic MRI or CT
scans. All patients were instructed to use vaginal dilator to
prevent vaginal adhesions and stenosis.
Patient who received EBRT in an outside centre (ﬁve patients)
were censored form this analysis of toxicity assessment. Statistical Analysis was done using IBM Statistics 20.

RESULTS
A total of 57 patients received brachytherapy at this Institute
from January 2008 till December 2015. The mean age of
patients was 53 ±12.5 years ranging from 24-83. The mean
duration of overall treatment time was 56 days. This group had
squamous cell carcinoma in 51 (90%) and adenocarcinoma in 5
(9%) of patients. Only one patient was diagnosed to have poorly
diﬀerentiated small cell carcinoma. All the patients were staged
according to FIGO staging system, 40 (70%) patients had FIGO
Stage IIb disease. Three patients had FIGO stage IVb disease by
virtue of paraortic lymphadenopathy, without any distant
metastasis.
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Table I: Road map to cervical cancer deﬁnitive treatment.
Weeks

Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

Sunday

1

CRT

RT

RT

RT

RT

Oﬀ

Oﬀ

2

CRT

RT

RT

RT

RT

Oﬀ

Oﬀ

3

CRT

RT

RT

RT

RT

Oﬀ

Oﬀ

4

CRT

RT

RT

RT

Smit’s sleeve insertion

Oﬀ

Oﬀ

5

CRT

RT

RT

RT

HDR 1

Oﬀ

Oﬀ

6

CRT

RT

Oﬀ

Oﬀ

HDR 2

Oﬀ

Oﬀ

7

Oﬀ

Oﬀ

Oﬀ

Oﬀ

HDR 3

Oﬀ

Oﬀ

CRT: Chemoradiation therapy; RT: Radiation therapy; HDR: High dose rate.

Figure 1: Anterior simulation X-Ray (inverted) image after insertion
of intracavitary applicators including a tandem and two ovoids. Blue
colour depicts 50% isodose coverage and red indicates 100% (8Gy)
coverage. Central green line denotes the Irridium-192 source stepping position in tandem and the two lateral green lines denote the
source stepping position in ovoids. Point A on right (Rt A) and left (Lt
A), bladder and rectal points are marked on this simulation X-Ray
image.

Out of 57 patients, 50 (88%) received external beam radiation therapy in this study. Conventional two-dimensional (2D) techniques four-ﬁeld box was used in ﬁve (9%) patients.
Three-dimensional conformal planning was used for 45
(79%) of the patients using Varian eclipse treatment planning system. Seven (12%) patients were referred to this
facility only for brachytherapy and are included in this analysis. Concurrent weekly chemotherapy was given to 55 of 57
patients. Cisplatin was given to 28 (49%) patients and combination of concurrent gemcitabine and cisplatin was given to
26 (46%) patients. Two patients were not given
chemotherapy because of advance age and poor performance status. Tandem and Ovoid Fletcher-Suit Delclos-style
Applicator Set was used for brachytherapy in 48 (84%)
patients and Ring Applicator was used in 9 (16%) of patients.
At the end of treatment, vaginal mucosal toxicity was
recorded for all of the patients. Grade II vaginal mucositis
was seen in 11 (19%) patients. Grade III mucositis was most
common, seen in 42 (73%). Only four (7%) patients had
grade IV vaginal mucositis at the end of treatment.
976

Figure 2: Lateral simulation X-Ray (inverted) image after insertion of
intracavitary applicators including a tandem and two ovoids (overlapping. Blue colour depicts 50% isodose coverage and red indicates
100% (8Gy) coverage. The longer green line denotes the Irridium-192
source stepping position in tandem and the two inferior green lines
denote the source stepping position in ovoids. Point A on right (Rt A)
and left (Lt A), bladder and rectal points are marked on this simulation X-Ray image. Contrast can be seen in rectum.

All patients were evaluated in clinic four weeks after the last
brachytherapy. Eighteen (32%) patients were observed to
have grade I vaginal mucositis, grade II mucositis was
present in 37 (65%) and only two (3.5%) patients had grade
III vaginal mucositis. Eight weeks after completion of treatment none of the patients had signiﬁcant vaginal toxicity.

DICSUSSION
Due to lack of vaccination, screening and awareness,
females with cervical cancer present with locally advanced
disease in Pakistan.8,9 In a case series from Pakistan, Hashmi
et al. has reported 66% of their patients belonging to stage
10
IIb, which is similar to this study’s experience of 70%.
Brachytherapy is an integral component in the management
of locally advanced cervical cancer as part of deﬁnitive treatment with chemo-radiation.3 Traditionally, low dose rate
brachytherapy regimens have been used. However, in more
and more facilities LDR is being replaced by HDR units on

Journal of the College of Physicians and Surgeons Pakistan 2020, Vol. 30(09): 974-979

Nasir Ali, Bilal Mazhar Qureshi, Ahmed Nadeem Abbasi, Asim Haﬁz, Benazir Mir Khan and Abdul Qadir Jangda

account of less cost of treatment, less potential complications, equivalent control and survival rates in favor of HDR
brachytherapy regimens.11-15 Till to date, there is wide variation in the dose schedule of HDR treatment.16 Optimum dose
schedule has not yet been deﬁned, and American
Brachytherapy Society authors carefully stated that
proposed recommendations have not tested clinically.4

The clinicians opted three fractions of HDR brachytherapy of
8 Gy each. The aim was to reduce the cost of treatment and
timely completion of chemoradiation therapy, but at the
same time vaginal mucosa toxicity was a concern. Therefore, vaginal mucosal toxicity was graded according to
CTCAE system and recorded at completion of HDR
brachytherapy, at 4 weeks and at eight weeks follow up. In
a prospective phase III trial single agent cisplatin was
compared with doublet of cisplatin and gemcitabine and all
patients received a total dose of 5040 cGy EBRT plus LDR
brachytherapy.12 It showed increased systemic toxicity using
doublet chemotherapy regimen. Systemic toxicity in these
patients was not higher that reported in that trial because
we used 4500 cGy over 25 fractions of EBRT plus HDR
brachytherapy in the two arms of chemotherapy regimens.
Since 2007, the dose fractionation has been three fractions
of 8 Gy each at point A. Vaginal grade III mucosal toxicity
was seen in equal proportion in both the chemotherapy regimens used (weekly concurrent cisplatin chemotherapy 40
2
2
mg/m in 25 patients or cisplatin 40 mg/m and gemcitabine
2
125 mg/m in other 25 patients), only in one patient from
Kenya who received concurrent cisplatin chemotherapy
alone, had iatrogenic longitudinal tear in vaginal mucosa in
ﬁrst fraction of HDR treatment, so she was not given subsequent two fractions of HDR and given boost of 14 Gy with
EBRT. Hashmi et al has reported complete response in 54%
and partial response in 38% patients with concurrent
cisplatin chemotherapy with only 43% patients having
vaginal mucositis.16 However, the timing of recording the
acute toxicity has not been elaborated. In the current study
the toxicity has been reported at three diﬀerent intervals.
Rectal and bladder point doses according to the ICRU calculation points at level of external os were kept less than 60%
13
of dose at point A. After two or three fractions, toxicity has
been reported similar to patients in the present study. In a
report by Petereit et al., authors were unable to identify a
total threshold dose or the number of fractions used that
could be taken as a factor contributing to the tissue compli14
cations.
Total duration of treatment is reported by several authors to
be of clinical signiﬁcance in patients treated by chemoradiation therapy.17-22 Scheduling of HDR implant also carried a
prognostic signiﬁcance for local control in patients with
locally advanced disease. Whenever patient’s anatomy
allows brachytherapy should be instituted in third week of
23
EBRT.

In the current study majority of the patients presented with
advanced disease, most patients being stage IIB, so
brachytherapy was instituted in last week of EBRT schedule
allowing for the tumor to shrink and to achieve a good
applicator geometry. Only 10 patients were able to
complete the entire treatment in less than 50 days, 25
patients were able to complete in 50-60 days, and 15 took
more than 60 days to complete treatment. The patients
who could not complete treatment in 50 days had delays
due to hematologic toxicity related to chemotherapy,
leading to interruptions in treatment or missed
chemotherapy cycles.
Response of cervical mass and toxicity was evaluated at
end of treatment, at 4 and 8 weeks. Though patients
receiving doublet chemotherapy regimen had slightly more
pronounced vaginal mucosal reactions, there was a trend
of improvement of these eﬀects at four week and eight
week follow up.
It is well known that cervical cancer is a one of the leading
problems for lower socio-economic strata, which are
already resource-limited. 24,25 This treatment strategy
provides a cost-eﬀective approach. The strategy can be
adapted by radiation facilities designed to oﬀer this curative treatment to large population. It is eﬀective in this
center as the patients are coming from far ﬂung areas and
mostly have to pay on their own.6

CONCLUSION
This series suggests that three fractions of HDR
brachytherapy applications are well tolerated by these
patients and toxicity is manageable. Although ABS guidelines has suggested to use 4-6 fractions to keep toxicity
less, it is being proposed that increasing the fractions
beyond 3 may prolong the treatment duration leading to
compromised outcome. Also using three fractions is costeﬀective in resource-limited setting, because patients come
from remote areas for treatment and have to pay on their
own. Long term disease control and toxicity remains to be
seen in this series of patients and will be reported after a
longer follow-up.
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